Giuseppe
Emeritus
[Source: US National Library of Medicine, (LINK). Edited.]
J Virol. 2010 May 5. [Epub ahead of print]
Attenuated Bordetella pertussis protects against highly pathogenic influenza A viruses by dampening the cytokine storm.
Li R, Lim A, Phoon MC, Narasaraju T, Ng JK, Poh WP, Sim MK, Chow VT, Locht C, Alonso S. - Department of Microbiology, Immunology Programme, Yong Loo Lin School of Medicine, National University of Singapore, CeLS building #03-05, 28 Medical Drive, Singapore 117597, Singapore; Department of Physiology, National University of Singapore, Singapore; Department of Pharmacology, National University of Singapore, Singapore; Inserm, U1019, F-59019 Lille, France; CNRS UMR8204, F-59019 Lille, France; Univ Lille Nord de France, F-59000 Lille, France; Institut Pasteur de Lille, F-59019 Lille, France.
The threat of a pandemic spread of highly virulent influenza A viruses currently represents a top global public health problem. Mass vaccination remains the most effective way to combat influenza. However, current vaccination strategies face the challenge to meet the demands in a pandemic situation. In a mouse model of severe influenza-induced pneumonitis, we observed that prior nasal administration of an attenuated strain of Bordetella pertussis (BPZE1) provided effective and sustained protection against lethal challenge with two different influenza A virus subtypes. In contrast to most cross-protective effects reported so far, the protective window offered upon nasal treatment with BPZE1 lasted up to at least 12 weeks, suggesting unique mechanism(s) involved in the protection. No significant differences in viral loads were observed between BPZE1-treated and control mice, indicating that the cross-protective mechanism(s) do not directly target the viral particles and/or infected cells. This was further confirmed by the absence of cross-reactive antibodies and T-cells in serum transfer and in vitro re-stimulation experiments, respectively. Instead, compared to infected control mice, BPZE1-treated animals displayed markedly reduced lung inflammation and tissue damage, decreased neutrophil infiltration, and strong suppression of the production of major pro-inflammatory mediators in their broncho-alveolar fluids. Our findings thus indicate that protection against influenza-induced severe pneumonitis can be achieved through attenuation of exaggerated cytokine-mediated inflammation. Furthermore, nasal treatment with live attenuated B. pertussis offers a potential alternative to conventional approaches in the fight against one of the most frightening current global public health threats.
PMID: 20444902 [PubMed - as supplied by publisher]
-
-----
J Virol. 2010 May 5. [Epub ahead of print]
Attenuated Bordetella pertussis protects against highly pathogenic influenza A viruses by dampening the cytokine storm.
Li R, Lim A, Phoon MC, Narasaraju T, Ng JK, Poh WP, Sim MK, Chow VT, Locht C, Alonso S. - Department of Microbiology, Immunology Programme, Yong Loo Lin School of Medicine, National University of Singapore, CeLS building #03-05, 28 Medical Drive, Singapore 117597, Singapore; Department of Physiology, National University of Singapore, Singapore; Department of Pharmacology, National University of Singapore, Singapore; Inserm, U1019, F-59019 Lille, France; CNRS UMR8204, F-59019 Lille, France; Univ Lille Nord de France, F-59000 Lille, France; Institut Pasteur de Lille, F-59019 Lille, France.
The threat of a pandemic spread of highly virulent influenza A viruses currently represents a top global public health problem. Mass vaccination remains the most effective way to combat influenza. However, current vaccination strategies face the challenge to meet the demands in a pandemic situation. In a mouse model of severe influenza-induced pneumonitis, we observed that prior nasal administration of an attenuated strain of Bordetella pertussis (BPZE1) provided effective and sustained protection against lethal challenge with two different influenza A virus subtypes. In contrast to most cross-protective effects reported so far, the protective window offered upon nasal treatment with BPZE1 lasted up to at least 12 weeks, suggesting unique mechanism(s) involved in the protection. No significant differences in viral loads were observed between BPZE1-treated and control mice, indicating that the cross-protective mechanism(s) do not directly target the viral particles and/or infected cells. This was further confirmed by the absence of cross-reactive antibodies and T-cells in serum transfer and in vitro re-stimulation experiments, respectively. Instead, compared to infected control mice, BPZE1-treated animals displayed markedly reduced lung inflammation and tissue damage, decreased neutrophil infiltration, and strong suppression of the production of major pro-inflammatory mediators in their broncho-alveolar fluids. Our findings thus indicate that protection against influenza-induced severe pneumonitis can be achieved through attenuation of exaggerated cytokine-mediated inflammation. Furthermore, nasal treatment with live attenuated B. pertussis offers a potential alternative to conventional approaches in the fight against one of the most frightening current global public health threats.
PMID: 20444902 [PubMed - as supplied by publisher]
-
-----